Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.
| Revenue (Most Recent Fiscal Year) | $10.59M |
| Net Income (Most Recent Fiscal Year) | $-68.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 107.53 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -24064.01% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -11.48% |
| Return on Assets (Trailing 12 Months) | -11.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 47.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 47.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.09M |
| Free Float | 55.23M |
| Market Capitalization | $1.40B |
| Average Volume (Last 20 Days) | 0.84M |
| Beta (Past 60 Months) | 2.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |